No Data
Novo Nordisk's New Weight-loss Drug Works Better, but Not as Well as Expected
FDA Approves Alhemo Injection as Once-daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older With Hemophilia A or B With Inhibitors
Top Gap Ups and Downs on Friday: NVO, BABA, INFY and More
Novo Nordisk Stock Crashes on Obesity Drug Data. It's a Win for Eli Lilly. -- Barrons.com
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Novo-Nordisk A/S Options Spot-On: On December 20th, 195.36K Contracts Were Traded, With 638.38K Open Interest
hardeep dhaliwal : Based on Company’s financial Statements it will fly….